Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size

Price

Stock

Quantity

100mg	USD 97	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (832) 582-8158 [email protected]

Cited by 23 Publications

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	MYXGeY5kfGmxbjDBd5NigQ>?	NEXncnAxNjFvM{Cg{txO	MlGyOFghcA>?		MYPpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	M2jYeFI3PTF\|MUey
H460	MXjGeY5kfGmxbjDBd5NigQ>?	NYTEVlZROC5zLUOwJO69VQ>?	MXG0PEBp		NYfmSpE4cW6mdXPld{BKS0GPLUGg[ZhxemW\|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?	NHrMbVMzPjVzM{G3Ni=>
HKESC-2	NUixZW9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnLNlDDqM7:TR?=	NHXKS2Q1QMLiaNMg		MmLhd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh	MlLNNlY1PzR4OUO=
CaES-17	M2LGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj0boQzOMLizszN	Mn33OFjDqGkEoB?=		NXrpPIVWe2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi	NGXHXG4zPjR5NE[5Ny=>
HKESC-2	NYnwcoptSXCxcITvd4l{KEG\|c3H5	NYLiXVZZOjEEoN88US=>	M1TZRVQ5yqCqwrC=		MXjy[YR2[2W\|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	Mk\GNlY1PzR4OUO=
CaES-17	NX7nWZZtSXCxcITvd4l{KEG\|c3H5	M3fRWlIxyqEQvF2=	M3nn[lQ5yqCqwrC=		NW\h[WxDemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	NIfnUIwzPjR5NE[5Ny=>
A549	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[yO5E2NTF4MDFOwG0>	M{ftUVQ5yqCqwrC=	NXW1[VY4TE2VTx?=	NFzFR41KSzVyPUG2N{41KM7:TR?=	NVnqNGdIOjZ2NkS2OFM>
HCC827	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUm1VGNnPS1zNkCg{txO	MUO0POKhcMLi	M33OTGROW09?	Ml7JTWM2OD14OT6yJO69VQ>?	M2TheVI3PDZ2NkSz
A549	NXiwb5VbSXCxcITvd4l{KEG\|c3H5	M3rwbFgxKML3TR?=	Mle3OFjDqGkEoB?=	M1nH[WROW09?	NWPERY5ucW6mdXPld{BieG:ydH;zbZM>	M3r6RVI3PDZ2NkSz
HCC827	M1HlWGFxd3C2b4Ppd{BCe3OjeR?=	MVy4NEDDvU1?	M4LoOVQ5yqCqwrC=	M1vrfWROW09?	NIDNbnlqdmS3Y3XzJIFxd3C2b4Ppdy=>	M1XC[VI3PDZ2NkSz
SGC-7901/DDP	NIjNNYdHfW6ldHnvckBCe3OjeR?=	NVPGR2pjOTEEoNM1US=>	Ml20NlQhcA>?		M{\ib4lvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44>	MUSyOlQxPzZ3Mx?=
SGC-7901	Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEHrPXQzPMLiaNMg		MUXJR\|UxRTFzNT6wPEDPxE1?	M3SxV\|I3PDB5NkWz
SGC-7901/DDP	MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYfpVZpLOjUEoHlCpC=>		NETSOWFKSzVyPUO1MlQ2KM7:TR?=	NITJPZYzPjRyN{[1Ny=>
SGC-7901/DDP	NHflcIxCeG:ydH;zbZMhSXO\|YYm=	NYLHSGJvOTEEoNM1US=>	NWjsUldIOjRiaB?=		MnjzbY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=>	MoSyNlY1ODd4NUO=
SGC-7901/DDP	M1nhR2Z2dmO2aX;uJGF{e2G7	NFrmOVAyOMLiwsXN	NW\KNpFvOjRiaB?=		NUnoeZdmcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC=	M3PKRlI3PDB5NkWz
SGC-7901/DDP	M{\kSWZ2dmO2aX;uJGF{e2G7	NX\NV\|ZEOTEEoNM1US=>	M17pdVI1KGh?		MnHUZ4F2e2W\|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu	NXPsWoxkOjZ2MEe2OVM>
H357	NFjyVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvEN\|VNPy53L{GwJO69VQ>?	MlXWOFghcA>?	NWrPfGVoTE2VTx?=	NE\mdI1qdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5	MXiyOlAxQTh5NB?=
TAF	NFjFToxHfW6ldHnvckBCe3OjeR?=	MnXpNVDDqML3TR?=	MoXUO{Bl		NUD2ZpRG[W[oZXP0d{BVSU[\|IHHkbIV{cX[nIIDyc5BmenSrZYO=	NX3Ze\|hQOjV7OEexNlc>
TAF	MWfGeY5kfGmxbjDBd5NigQ>?	NFfqN3cyOMLiwsXN	M{XGPFMxNTF{MDDtbY4>		MnfadI9wemy7IHHm[oVkfHNiZFHreEBxcG:\|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n	Mn71NlU6QDdzMke=
TAF	NI[1RldHfW6ldHnvckBCe3OjeR?=	NVjE[YM4OTEEoNM1US=>	NVfOZWViPDhiaB?=		M4TmNIlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MXSyOVk5PzF{Nx?=
PANC-1	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;mb\|czOC94MD:xNFAh\|ryP	MVOyOE81QC95MjDo		NV[2Tox3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NEW2cGMzPTl5M{C2Ni=>
PANC-1	MV\GeY5kfGmxbjDBd5NigQ>?	MVeyNE83OC9zMECg{txO	MY[yOEBp		MknvZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh	MXSyOVk4OzB4Mh?=
HeLa	NEXvW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfPWnR5OjEEoN88UeKh	NHz0SmIzPMLiaB?=		NUTCdHZL\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36=	NFfZV3ozPTd5MESyNy=>
SACC-83	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfvUG5wOjEEoN88UeKh	MV2yOOKhcA>?		MVPlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	MknHNlU4PzB2MkO=
HeLa	M13WN2Fxd3C2b4Ppd{BCe3OjeR?=	M4DlflIxyqEQvF5CpC=>	MVWyOOKhcA>?		NI[0[I1mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{	MVqyOVc4ODR{Mx?=
SACC-83	MX\BdI9xfG:\|aYOgRZN{[Xl?	NIj0flczOMLizszNxsA>	MYiyOOKhcA>?		NUDFbmFs\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	NGX4[JQzPTd5MESyNy=>
HeLa	NWfISXFuTnWwY4Tpc44hSXO\|YYm=	M4OwTFIxNzRyL{iwJO69VQ>?	Moe0NlTDqGh?		NH3LZZV2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	MVqyOVc4ODR{Mx?=
SACC-83	Mn7VSpVv[3Srb36gRZN{[Xl?	NYrXN3hHOjBxNECvPFAh\|ryP	NXzlNWd1OjUEoHi=		NIPtVFJ2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	NUmxTlRDOjV5N{C0NlM>
HLCZ01	NGfsU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVuxd5dSOOLCk{[wxsDDvU1?	MYi0PEBp	NIe4dGJFVVOR	NX[xWppDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NUDqbmY6OjV5MkS4PVk>
HLCZ01	MXPGeY5kfGmxbjDBd5NigQ>?	MluwOFDDqM7:TR?=	MYCyOEBp	MVrEUXNQ	M1u4Uolv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS\|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE>	MX:yOVczPDh7OR?=
HLCZ01	NYnJ[I9kSXCxcITvd4l{KEG\|c3H5	MnG2OFDDqM7:TR?=	MUOyOEBp	MYnEUXNQ	M2\VXYVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	M2PMcFI2PzJ2OEm5
HLCZ01	NV:2T3R{TnWwY4Tpc44hSXO\|YYm=	MnLiOFDDqM7:TR?=	MWWyOEBp	MoT1SG1UVw>?	NXnPUZZUcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y	MX2yOVczPDh7OR?=
MGC803	NH;XWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\WNE03OCEQvF2=	NFXnVlI4OiCq		MljUTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2=	MkD3NlU4ODF\|N{i=
SGC7901	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13ESFAuPjBizszN	NX3jbFBnPzJiaB?=		MYHJR\|UxRTR\|LkWz5qCKyrIkgJm1MlEzKM7:TR?=	NWPrZ\|A{OjV5MEGzO\|g>
MGC803	M{S1V2Z2dmO2aX;uJGF{e2G7	M3fNZlQxyqEQvF2=	M3LmN\|gwOTZxMkSgbC=>		NXT0bm1nfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	MV[yOVcxOTN5OB?=
SGC7901	M{Xj[mZ2dmO2aX;uJGF{e2G7	NHmwW2s1OMLizszN	NV;KNGRlQC9zNj:yOEBp		M4\NfZVxemWpdXzheJMhS2KuLXKg[ZhxemW\|c3nvci=>	NF6xWFAzPTdyMUO3PC=>
MCF-7	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXHbYgyNzFyIN88US=>	Ml\rO\|IhcA>?	MoThSG1UVw>?	MmPR[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25?	M4XmcFI2PjZ5NUGw
MDA-MB-231	M1jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3oPVgyNzFyIN88US=>	M3;DdFczKGh?	M{[3T2ROW09?	NEDoR5RmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	M1vxTlI2PjZ5NUGw
MDA-MB-231	MnrWSpVv[3Srb36gRZN{[Xl?	MniwNE01OCEEtV2=	NYC1NIk4PC1{NDDo		MWfpcoNz\WG\|ZYOgR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NXrpcnNwOjV3OEezNlk>
MCF-7	NUH1S4duTnWwY4Tpc44hSXO\|YYm=	NXrNeIt4OC12MDFCuW0>	NF7mR2w1NTJ2IHi=		MXnlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	NIq0UlAzPTV6N{OyPS=>
MCF7-MX	MoP1SpVv[3Srb36gRZN{[Xl?	NITkdVkxNTRyINM1US=>	MV60MVI1KGh?		MXHlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	NHX3emszPTV6N{OyPS=>
MDA-MB-231	NXHNfI9yTnWwY4Tpc44hSXO\|YYm=	M{D5[FAuPDBiwsXN	MYS0MVI1KGh?		NHrrcGp{fGmvdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=	MWGyOVU5PzN{OR?=
A2780	NYfJVo5sTnWwY4Tpc44hSXO\|YYm=	M33HUVUwOTBxMUWg{txO	NGPHO4E1QCCq		MWDk[YNz\WG\|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NICyUY0zPTR{NEi5PC=>
SKOV3	MofkSpVv[3Srb36gRZN{[Xl?	MnzVOU8yOC9zNTFOwG0>	NYTscY44PDhiaB?=		MmTw[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MlnINlU1OjR6OUi=
A2780	NXe3bokyTnWwY4Tpc44hSXO\|YYm=	NVzoUHJrPS9zMD:xOUDPxE1?	NFPhNok1QCCq		M2rVPYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	MnjJNlU1OjR6OUi=
SKOV3	M{HSO2Z2dmO2aX;uJGF{e2G7	NUjDXYo{PS9zMD:xOUDPxE1?	NUHXUXlOPDhiaB?=		MnPl[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>?	M1fCblI2PDJ2OEm4
A2780	NFTuNmtHfW6ldHnvckBCe3OjeR?=	NVjlSZVpPS9zMD:xOUDPxE1?	M2jHSVQ5KGh?		M{PodIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?=	NXvCeYpxOjV2MkS4PVg>
SKOV3	Ml7KSpVv[3Srb36gRZN{[Xl?	MYS1M\|ExNzF3IN88US=>	M{P1b\|Q5KGh?		MoDY[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw	MWeyOVQzPDh7OB?=
A2780	NXvDdFRkTnWwY4Tpc44hSXO\|YYm=	MkS5OU8yOC9zNTFOwG0>	NHvRN\|cyKGh?		MnzYbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MXeyOVQzPDh7OB?=
SKOV3	MVLGeY5kfGmxbjDBd5NigQ>?	NUTHbpI1PS9zMD:xOUDPxE1?	NFXBNHQyKGh?		NF:zRpZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NWPBVY5TOjV2MkS4PVg>
HCT-15	NWq4NnNGTnWwY4Tpc44hSXO\|YYm=	NGLMUVIyOC13MDFOwG0>	M{\HeFYuOzZiaB?=		NILa[m5qdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MojhNlUzOThyMki=
HT-29	M2Xr[mZ2dmO2aX;uJGF{e2G7	MWexNE02OCEQvF2=	NIO2V5E3NTN4IHi=		NWj6XHpWcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NXHFVGV{OjV{MUiwNlg>
HSC3	NH[5WYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MV6w5qCUPDBizszN	Ml;oOFghcA>?		NW\3PZB[UUN3ME2yOU42yrFzLke4NEDPxE1?	M4PsbFI2OTl6N{i5
HSC3	MlO5RZBweHSxc3nzJGF{e2G7	NUDUSWl7OjVizszN	Mn3vOFghcA>?		Ml;abY5lfWOnczDhdI9xfG:\|aYO=	NX3JZXhiOjVzOUi3PFk>
HSC3	NUXvNYM4TnWwY4Tpc44hSXO\|YYm=	NVTDTWtGOjVizszN	MkfWOFghcA>?		M4fZPYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR?	MYmyOVE6QDd6OR?=
HSC3	NYm0[Zc6TnWwY4Tpc44hSXO\|YYm=	NVG0[ZJ{OjVizszN	Ml7xOFghcA>?		MWTpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS=	NG\BVVYzPTF7OEe4PS=>
HSC3	M{DjT2Z2dmO2aX;uJGF{e2G7	NWXhcZN[OjVizszN	Mn;BO\|IhcA>?		MXfk[YNz\WG\|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6\|wrC=	NH3VZVUzPTF7OEe4PS=>
201T	NEDVcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{nHOlczKGh?	NGXz[pNFVVOR	M1TiNmlEPTB;NEiuOkDDvU1?	NGrkR4wzPTB3N{m0NS=>
273T	M13tbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYq3NkBp	NFLiRnhFVVOR	NXrDcodlUUN3ME24NE42KML3TR?=	MkDnNlUxPTd7NEG=
Hep-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHaN\|AwPTBxMUCwJO69VQ>?	MYKxNk8zPC9\|Nj:0PEBp	MWTEUXNQ	M1HFbIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{Oyc\|I1QTl6NU[0
Hep-2	MWjBdI9xfG:\|aYOgRZN{[Xl?	NULWd\|NRPTBizszN	NUnuc29lOC12ODDo	MnHiSG1UVw>?	NYjZcGlmcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	NXW1TW8zOjR7OUi1OlQ>
Hep-2	NXnqR3NWTnWwY4Tpc44hSXO\|YYm=	M3rsVVUxKM7:TR?=	NHfrNoIxNTR6IHi=	NEn6[JpFVVOR	M3rONpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7	MnG0NlQ6QTh3NkS=
Hep-2	Ml:2SpVv[3Srb36gRZN{[Xl?	Mk[5OVAh\|ryP	M4Lue\|AuPDhiaB?=	NUXyZZBDTE2VTx?=	NGrFfJZl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>?	NImwXoczPDl7OEW2OC=>
SGC-7901	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXzbWxXOTBxNUCvNVAxKM7:TR?=	MXiyOE81QC95MjDo	MXfEUXNQ	MmmybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MWiyOFk6Ojl3OB?=
MKN-45	NESzdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxNE82OC9zMECg{txO	MlL0NlQwPDhxN{KgbC=>	MnThSG1UVw>?	NFLZbIdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NWDBOFRUOjR7OUK5OVg>
SGC-7901	M2nvd2Z2dmO2aX;uJGF{e2G7	M1L0O\|ExNzVyL{GwNEDPxE1?	MlnyOFghcA>?	M4m5W2ROW09?	MnXl[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NVjKfpV{OjR7OUK5OVg>
MKN-45	MmT1SpVv[3Srb36gRZN{[Xl?	M4fhd\|ExNzVyL{GwNEDPxE1?	MYm0PEBp	NXr3SXJiTE2VTx?=	MWHkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NGLS[\|gzPDl7Mkm1PC=>
C666-1	M2XRbWN6fG:2b4jpZ4l1gSCDc4PhfS=>	NF\l[FYzOC16MDFOwG0>	NEjxc3QzPCCq		NYixSIZI\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	NF;3N3EzPDh3NEizPC=>
CNE-1	NHfjbpJEgXSxdH;4bYNqfHliQYPzZZk>	NGXyR5QzOC16MDFOwG0>	M3fGdlI1KGh?		M1Hwe4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	MoLVNlQ5PTR6M{i=
CNE-2	NEm4S4pEgXSxdH;4bYNqfHliQYPzZZk>	MnHtNlAuQDBizszN	M2\6XVI1KGh?		MV3k[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg	NVrFZYI1OjR6NUS4N\|g>
C666-1	NH7BOppEgXSxdH;4bYNqfHliQYPzZZk>	NEfyWYM3OCEQvF2=	NVXuOWUxPyCm		NUL2Z5BJ\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	NGrRWlczPDh3NEizPC=>
CNE-1	NH7nbmJEgXSxdH;4bYNqfHliQYPzZZk>	NE\xR4Y3OCEQvF2=	NEO4RW44KGR?		MlLR[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK=	M1TzclI1QDV2OEO4
SNU-1041	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzrcJZyOC12MDFOwG0>	NUnjVHFJPDhiaB?=		NXXDUJdCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M2XofFI1Pjl{N{Cz
SNU-1041	M1PwPGZ2dmO2aX;uJGF{e2G7	MVOyNE8{OCEQvF2=	M4HyR\|QhcA>?		NIDEW2RqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	NGXlPZMzPDZ7MkewNy=>
SNU-1041	Mn\5SpVv[3Srb36gRZN{[Xl?	NXXiWHdCOC12MDFOwG0>	M4fxflQhcA>?		MWr1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>?	MV6yOFY6OjdyMx?=
SGC-7901	M3O0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWm1NE0yOjVizszN	NWCxWGRbOjRxNEivO\|IhcA>?		MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M2XlT\|I1Pjd4M{m0
SGC-7901	NGD3dWpCeG:ydH;zbZMhSXO\|YYm=	MVuxNFAh\|ryP	MmTVO\|IhcA>?		MUfpcoR2[2W\|IHHwc5B1d3Orcx?=	MnjyNlQ3PzZ\|OUS=
SGC-7901	NEe1eoJHfW6ldHnvckBCe3OjeR?=	MoXHO\|UwOTByL{GyOUDPxE1?	NWO0S45COjRxNEivO\|IhcA>?		NXf6WWRMcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO\|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI>	NUTlRXllOjR4N{[zPVQ>
LMeC	NEPCNpVHfW6ldHnvckBCe3OjeR?=	NF\3Z5kzOC93MDFOwG0>	MnTMOFghcA>?		NX;vXoRp\GWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEORWD2yJJBzd3SnaX6=	M{HpXFI1PjV4N{S2
CMeC-1	NGPEcoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NH22R3ozOC93MDFOwG0>	M3vLOlQ5KGh?		NVP3PXc3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NI\pSXAzPDZ3Nke0Oi=>
LMeC	NXv1XHY1S2WubDDWbYFjcWyrdImgRZN{[Xl?	MVeyNE82OCEQvF2=	NXTjTY0yPDhiaB?=		M4\TVIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Mn\qNlQ3PTZ5NE[=
CMeC-1	NXzZPZQ{TnWwY4Tpc44hSXO\|YYm=	NXjVNoRNOjBxNUCg{txO	NEHTR5Y1QCCq		NXvpV4ptcW6mdXPld{BIOS2VIHHydoV{fA>?	NFPhTIwzPDZ3Nke0Oi=>
LMeC	NFu0eHpHfW6ldHnvckBCe3OjeR?=	MkLUNlAwPTBizszN	MUK0PEBp		Ml7NbY5lfWOnczDHNU1UKGG{cnXzeC=>	MWWyOFY2Pjd2Nh?=
CMeC-1	NY\PbotNTnWwY4Tpc44hSXO\|YYm=	NYfyPJVTOjBxNUCg{txO	M2HoelQ5KGh?		Mne4[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NUTkOXNOOjR4NU[3OFY>
LMeC	MYrGeY5kfGmxbjDBd5NigQ>?	Mnf5NlAwPTBizszN	NGe0NlI1QCCq		NUfHTIky\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NWnmWnR5OjR4NU[3OFY>
CMeC-1	MnTmSpVv[3Srb36gRZN{[Xl?	MX:yNE82OCEQvF2=	MX[0PEBp		NI\hR3VqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MnzzNlQ3PTZ5NE[=
LMeC	MUTGeY5kfGmxbjDBd5NigQ>?	NGPnV5YzOC93MDFOwG0>	MmL4OFghcA>?		NYCyWoZ7cW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>?	NFOxNYozPDZ3Nke0Oi=>
OVCAR-3	MlnzR4VtdCCYaXHibYxqfHliQYPzZZk>	MV6xNEDDvU1?	NHqxbG8yKGh?		NF3BUWFmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh	Mn3zNlQ2OjB{Mke=
OVCAR-3	M4PNPGFxd3C2b4Ppd{BCe3OjeR?=	NWW3Zo8zOTBiwsXN	NXPsWVFYOSCq		MnfCdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	NFvYVGwzPDV{MEKyOy=>
OVCAR-3	NXnJ[IR7TnWwY4Tpc44hSXO\|YYm=	NGTsSFYyOCEEtV2=	NHPrWFYyKGh?		NFzIeVdmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=>	MlXSNlQ2OjB{Mke=
OVCAR-3	NF3hO\|hHfW6ldHnvckBCe3OjeR?=	MmX2NVAhyrWP	M1;QN\|EhcA>?		M{H6R4Rwf25vcnXneYxifGW\|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>	NWrUSYFZOjR3MkCyNlc>
OVCAR-3	NYLJd\|VtTnWwY4Tpc44hSXO\|YYm=	M4H3flExKML3TR?=	MUWxJIg>		NIXy[ndqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?	NIDVd5czPDV{MEKyOy=>
CF33	NVnCfFhDTnWwY4Tpc44hSXO\|YYm=	NWr2cHNvOTByIN88US=>	NHjEZWgzPCCq		NHXsZnhqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?=	MUSyOFUxOzd6Mh?=
CF33	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DhVVExNTFyMDFOwG0>	NXPyNIJHOC12IHS=		MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NVvsfVlHOjR3MEO3PFI>
CF33	MYTGeY5kfGmxbjDBd5NigQ>?	M3u1ZlExNTFyMDFOwG0>	MUG0MVI1KGh?		M4e2e4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy\|IHnuJGcxN0dzIHHydoV{fA>?	MVGyOFUxOzd6Mh?=
LNCaP	NFLLbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLwWlZuOi93L{GwJO69VQ>?	MmHZPVYhcA>?		NVPjeWVScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	NXHnSI9sOjR{OU[5O\|g>
LNCaP	MlO5RZBweHSxc3nzJGF{e2G7	MlPMNk82NzFyIN88US=>	MYO5OkBp		NUDkUXFjcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG\|dHH0bY4>	MXmyOFI6Pjl5OB?=
PC-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LP[VAuPTBizszN	NYLwW\|FIPDkkgJno		NFPyWlRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MkHxNlQyOjd6OEK=
PC-3	MmS0R4VtdCCYaXHibYxqfHliQYPzZZk>	NVrkdVEyOC1zMECg{txO	M3jHbVczKGh?		NVzGblFK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M2fONVI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SC 58635

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Not yet recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	June 30 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable
NCT03541655	Active not recruiting	Drug: Bupivacaine HCl\|Drug: F14 (celecoxib)	Total Knee Replacement\|Postoperative Pain	Arthritis Innovation Corporation	May 4 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type